Identification

Name
Terconazole
Accession Number
DB00251  (APRD00659)
Type
Small Molecule
Groups
Approved
Description

Terconazole is an anti-fungal medication, primarily used to treat vaginal fungal infections. [Wikipedia]

Structure
Thumb
Synonyms
Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Taro-terconazole CreamCream0.4 %VaginalTaro Pharmaceuticals, Inc.2004-09-21Not applicableCanada
Terazol 3Suppository80 mg/1VaginalOrtho Mc Neil Janssen Pharmaceutical1988-06-272016-10-13Us
Terazol 3Cream8 mg/gVaginalJanssen Pharmaceuticals1991-02-21Not applicableUs
Terazol 3Cream8 mg/gVaginalA S Medication Solutions1991-02-212017-06-20Us
Terazol 3Cream8 mg/gVaginalOrtho Mc Neil Janssen Pharmaceutical1991-02-212016-10-13Us
Terazol 3Suppository80 mg/1VaginalJanssen Pharmaceuticals1988-05-24Not applicableUs
Terazol 3 Vaginal Cream 0.8%Cream0.8 %VaginalJanssen Pharmaceuticals1992-12-312007-08-11Canada
Terazol 3 Vaginal Ovules 80mgInsert80 mgVaginalJanssen Pharmaceuticals1991-12-312008-08-08Canada
Terazol 7Cream4 mg/gVaginalJanssen Pharmaceuticals1987-12-31Not applicableUs
Terazol 7Cream4 mg/gVaginalOrtho Mc Neil Pharmaceuticals1988-06-272017-06-30Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TerconazoleCream4 mg/gVaginalTaro Pharmaceuticals U.S.A., Inc.2005-01-19Not applicableUs
TerconazoleCream4 mg/gVaginalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2005-02-18Not applicableUs
TerconazoleCream8 mg/gVaginalA S Medication Solutions2004-04-062017-06-20Us
TerconazoleCream8 mg/gVaginalPhysicians Total Care, Inc.2004-11-18Not applicableUs
TerconazoleCream8 mg/gVaginalTaro Pharmaceuticals U.S.A., Inc.2004-04-06Not applicableUs
TerconazoleCream4 mg/gVaginalA S Medication Solutions2005-01-19Not applicableUs
TerconazoleCream4 mg/gVaginalRebel Distributors2005-01-19Not applicableUs
TerconazoleSuppository80 mg/1VaginalTaro Pharmaceuticals U.S.A., Inc.2007-03-09Not applicableUs
TerconazoleSuppository80 mg/1VaginalPerrigo New York Inc.2006-08-28Not applicableUs
TerconazoleSuppository80 mg/1VaginalGw Pharmaceuticals Ltd.2015-09-25Not applicableUs
International/Other Brands
Terazol / Terazol 3
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Terazol 3 Dual PakTerconazole (0.8 %) + Terconazole (80 mg)Cream; Insert; KitVaginalJanssen Pharmaceuticals1994-12-312014-03-19Canada
Terazol 3 Dual PakTerconazole (0.8 %) + Terconazole (80 mg)Cream; Insert; KitVaginalJanssen Pharmaceuticals1994-12-312014-03-19Canada
Categories
UNII
0KJ2VE664U
CAS number
67915-31-5
Weight
Average: 532.462
Monoisotopic: 531.180395297
Chemical Formula
C26H31Cl2N5O3
InChI Key
BLSQLHNBWJLIBQ-OZXSUGGESA-N
InChI
InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1
IUPAC Name
1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(propan-2-yl)piperazine
SMILES
CC(C)N1CCN(CC1)C1=CC=C(OC[[email protected]]2CO[[email protected]@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1

Pharmacology

Indication

For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.

Structured Indications
Pharmacodynamics

Terconazole is a triazole antifungal agent available for intravaginal use. It is structurally related to imidazole-derivative antifungal agents, although terconazole and other triazoles have 3 nitrogens in the azole ring. By inhibiting the 14-alpha-demethylase (lanosterol 14-alpha-demethylase), Terconazole inhibits ergosterol synthesis. Depletion of ergosterol in fungal membrane disrupts the structure and many functions of fungal membrane leading to inhibition of fungal growth.

Mechanism of action

Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 14-alpha-demethylase in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth.

TargetActionsOrganism
ALanosterol 14-alpha demethylase
antagonist
Yeast
Absorption

Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations

Volume of distribution
Not Available
Protein binding

94.9%

Metabolism

Systemically absorbed drug appears to be rapidly and extensively metabolized. Terconazole primarily undergoes oxidatative N- and O-dealkylation, dioxolane ring cleavage, and conjugation.

Route of elimination

Following oral (30 mg) administration of 14C-labelled terconazole, excretion of radioactivity was both by renal (32-56%) and fecal (47-52%) routes.

Half life

6.9 hours (range 4.0-11.3)

Clearance
Not Available
Toxicity

The oral LD50 values were found to be 1741 and 849 mg/kg for the male and female in rat.

Affected organisms
  • Fungi
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AmlodipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Terconazole.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Terconazole is combined with Amrinone.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Terconazole is combined with Atorvastatin.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Terconazole is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Barnidipine.Approved
BencyclaneThe risk or severity of adverse effects can be increased when Terconazole is combined with Bencyclane.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Benidipine.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Terconazole is combined with Bepridil.Approved, Withdrawn
BuspironeThe metabolism of Buspirone can be decreased when combined with Terconazole.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Terconazole.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Terconazole is combined with Caroverine.Experimental
CerivastatinThe risk or severity of adverse effects can be increased when Terconazole is combined with Cerivastatin.Withdrawn
CilnidipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Terconazole is combined with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Terconazole.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Clevidipine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Terconazole.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Terconazole.Approved, Investigational, Vet Approved
DarodipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Terconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Terconazole is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Terconazole.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Terconazole.Approved
DotarizineThe risk or severity of adverse effects can be increased when Terconazole is combined with Dotarizine.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Efonidipine.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Terconazole is combined with Eperisone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Terconazole.Approved
FelodipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Terconazole is combined with Fendiline.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Terconazole is combined with Flunarizine.Approved
FluvastatinThe risk or severity of adverse effects can be increased when Terconazole is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Terconazole can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Terconazole is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Terconazole is combined with Gallopamil.Investigational
IsradipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Isradipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Terconazole is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Lercanidipine.Approved, Investigational
LidoflazineThe risk or severity of adverse effects can be increased when Terconazole is combined with Lidoflazine.Experimental
LosartanThe metabolism of Losartan can be decreased when combined with Terconazole.Approved
LovastatinThe risk or severity of adverse effects can be increased when Terconazole is combined with Lovastatin.Approved, Investigational
Magnesium SulfateThe risk or severity of adverse effects can be increased when Terconazole is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Manidipine.Approved, Investigational
MevastatinThe risk or severity of adverse effects can be increased when Terconazole is combined with Mevastatin.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Terconazole is combined with Mibefradil.Investigational, Withdrawn
NaftopidilThe risk or severity of adverse effects can be increased when Terconazole is combined with Naftopidil.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Terconazole is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Terconazole is combined with Nitrendipine.Approved, Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Terconazole is combined with Otilonium.Experimental, Investigational
PerhexilineThe risk or severity of adverse effects can be increased when Terconazole is combined with Perhexiline.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Terconazole.Approved, Vet Approved
PimozideTerconazole may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Terconazole is combined with Pinaverium.Approved
PitavastatinThe risk or severity of adverse effects can be increased when Terconazole is combined with Pitavastatin.Approved
PravastatinThe risk or severity of adverse effects can be increased when Terconazole is combined with Pravastatin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Terconazole is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Terconazole is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Terconazole.Approved, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Terconazole.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Terconazole.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Terconazole.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Terconazole.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Terconazole.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Terconazole.Approved, Investigational
RisedronateThe risk or severity of adverse effects can be increased when Terconazole is combined with Risedronate.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Terconazole is combined with Rosuvastatin.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Terconazole is combined with Simvastatin.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Terconazole.Approved
SucralfateSucralfate can cause a decrease in the absorption of Terconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Terconazole.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Terconazole.Approved, Investigational
TerodilineThe risk or severity of adverse effects can be increased when Terconazole is combined with Terodiline.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Terconazole is combined with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Terconazole is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Terconazole is combined with Tranilast.Approved, Investigational
UbidecarenoneThe risk or severity of adverse effects can be increased when Terconazole is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Terconazole.Approved
VerapamilThe risk or severity of adverse effects can be increased when Terconazole is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Terconazole is combined with Vinpocetine.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Terconazole is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Terconazole is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Terconazole.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14396
KEGG Drug
D00888
KEGG Compound
C08080
PubChem Compound
441383
PubChem Substance
46505257
ChemSpider
390122
BindingDB
50375318
ChEBI
82980
ChEMBL
CHEMBL1306
Therapeutic Targets Database
DAP000629
PharmGKB
PA164768834
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Terconazole
ATC Codes
G01AG02 — Terconazole
AHFS Codes
  • 84:04.08.08 — Azoles
FDA label
Download (33.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHIV Prevention1
3CompletedTreatmentVaginal Infections1
3RecruitingTreatmentVaginal Infections1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Altana inc
  • Nycomed us inc
  • Taro pharmaceuticals usa inc
  • Ortho mcneil janssen pharmaceutical inc
  • Perrigo new york inc
Packagers
Dosage forms
FormRouteStrength
CreamVaginal0.4 %
CreamVaginal8 mg/g
SuppositoryVaginal80 mg/1
Cream; insert; kitVaginal
CreamVaginal0.8 %
InsertVaginal80 mg
CreamVaginal4 mg/g
CreamVaginal4 mg
Prices
Unit descriptionCostUnit
Terazol 3 0.8% Cream 20 gm Tube55.99USD tube
Terazol 7 0.4% Cream 45 gm Tube54.0USD tube
Terazol 3 3 80 mg Suppository Box53.99USD box
Terconazole 3 80 mg Suppository Box50.9USD box
Terconazole 0.4% Cream 45 gm Tube42.57USD tube
Terconazole 0.8% Cream 20 gm Tube42.57USD tube
Terazol 3 cream2.64USD g
Zazole 0.8% vaginal cream2.54USD g
Terconazole 0.8% cream2.35USD g
Terazol 7 cream1.17USD g
Terconazole 0.4% cream0.96USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)126.3 °CNot Available
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0116 mg/mLALOGPS
logP4.58ALOGPS
logP5.37ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)8.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area64.88 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity153.19 m3·mol-1ChemAxon
Polarizability56.15 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9926
Blood Brain Barrier+0.6657
Caco-2 permeable+0.6081
P-glycoprotein substrateSubstrate0.7064
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.7891
Renal organic cation transporterInhibitor0.5272
CYP450 2C9 substrateNon-substrate0.8484
CYP450 2D6 substrateNon-substrate0.8227
CYP450 3A4 substrateSubstrate0.6986
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8354
Ames testNon AMES toxic0.5825
CarcinogenicityNon-carcinogens0.7686
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8114 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6633
hERG inhibition (predictor II)Inhibitor0.603
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00o0-3971230000-dd66741ee49b1efec5ef

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Aminophenyl ethers / Phenoxy compounds / Dichlorobenzenes / Dialkylarylamines / Aniline and substituted anilines / Alkyl aryl ethers / N-alkylpiperazines / Ketals / Aryl chlorides
show 9 more
Substituents
Phenylpiperazine / N-arylpiperazine / Aminophenyl ether / 1,3-dichlorobenzene / Phenoxy compound / Phenol ether / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Alkyl aryl ether
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
1-(4-\{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy\}phenyl)-4-isopropylpiperazine (CHEBI:82980)

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
Yes
Actions
Antagonist
General Function
Sterol 14-demethylase activity
Specific Function
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name
ERG11
Uniprot ID
P10613
Uniprot Name
Lanosterol 14-alpha demethylase
Molecular Weight
60674.965 Da
References
  1. Vanden Bossche H, Marichal P: Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9. [PubMed:1951574]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  3. Cauwenbergh G, Vanden Bossche H: Terconazole. Pharmacology of a new antimycotic agent. J Reprod Med. 1989 Aug;34(8 Suppl):588-92. [PubMed:2677363]

Drug created on June 13, 2005 07:24 / Updated on December 04, 2017 13:13